Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

Company Overview - Amneal Pharmaceuticals, Inc. is a fully integrated global pharmaceuticals company headquartered in Bridgewater, NJ, with a diverse portfolio of over 270 pharmaceutical products primarily in the United States [3] - The company operates in two main segments: Generics, focusing on complex product categories including injectables and biosimilars, and Specialty, which includes branded pharmaceuticals for central nervous system and endocrine disorders [3] Product Launches - In 2023, Amneal launched 39 new retail and injectable medicines, a significant increase from 26 new launches in 2022 [1] - In the fourth quarter of 2023 alone, the company introduced 13 new products, including 5 injectables such as potassium phosphate vials, tranexamic acid, and esmolol intravenous bags [1] - Key retail products launched in the fourth quarter include spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules [1] R&D Focus - The R&D portfolio of Amneal prioritizes complex and high-value products aimed at providing better access to affordable medicines for providers and patients [2]